{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:33:10Z","timestamp":1788201190220,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:00:00Z","timestamp":1631577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:00:00Z","timestamp":1631577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s12325-021-01903-7","type":"journal-article","created":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T21:13:46Z","timestamp":1631654026000},"page":"5345-5360","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9063-7229","authenticated-orcid":false,"given":"Jonathan","family":"Barratt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wladyslaw","family":"Sulowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sch\u00f6mig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Reusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Botond","family":"Csiky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,14]]},"reference":[{"issue":"3","key":"1903_CR1","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1159\/000455166","volume":"45","author":"F Locatelli","year":"2017","unstructured":"Locatelli F, Fishbane S, Block GA, Macdougall IC. Targeting hypoxia-inducible factors for the treatment of anemia in chronic kidney disease patients. Am J Nephrol. 2017;45(3):187\u201399.","journal-title":"Am J Nephrol"},{"issue":"10","key":"1903_CR2","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2011111078","volume":"23","author":"JL Babitt","year":"2012","unstructured":"Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012;23(10):1631\u20134.","journal-title":"J Am Soc Nephrol"},{"key":"1903_CR3","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1046\/j.1523-1755.64.s87.6.x","volume":"87","author":"AA Pereira","year":"2003","unstructured":"Pereira AA, Sarnak MJ. Anemia as a risk factor for cardiovascular disease. Kidney Int Suppl. 2003;87:S32\u20139.","journal-title":"Kidney Int Suppl"},{"issue":"1","key":"1903_CR4","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1186\/s12882-019-1554-0","volume":"20","author":"Y Ingrasciotta","year":"2019","unstructured":"Ingrasciotta Y, Lacava V, Marciano I, Giorgianni F, Tripepi G, Graziella DA, et al. In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study. BMC Nephrol. 2019;20(1):359.","journal-title":"BMC Nephrol"},{"issue":"4","key":"1903_CR5","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1440-1797.2007.00810.x","volume":"12","author":"DW Johnson","year":"2007","unstructured":"Johnson DW, Pollock CA, Macdougall IC. Erythropoiesis-stimulating agent hyporesponsiveness. Nephrology (Carlton). 2007;12(4):321\u201330.","journal-title":"Nephrology (Carlton)"},{"issue":"9","key":"1903_CR6","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJM199808273390903","volume":"339","author":"A Besarab","year":"1998","unstructured":"Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339(9):584\u201390.","journal-title":"N Engl J Med"},{"issue":"21","key":"1903_CR7","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","volume":"361","author":"MA Pfeffer","year":"2009","unstructured":"Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019\u201332.","journal-title":"N Engl J Med"},{"issue":"20","key":"1903_CR8","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1056\/NEJMoa065485","volume":"355","author":"AK Singh","year":"2006","unstructured":"Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085\u201398.","journal-title":"N Engl J Med"},{"issue":"4","key":"1903_CR9","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1203165","volume":"368","author":"S Fishbane","year":"2013","unstructured":"Fishbane S, Schiller B, Locatelli F, Covic AC, Provenzano R, Wiecek A, et al. Peginesatide in patients with anemia undergoing hemodialysis. N Engl J Med. 2013;368(4):307\u201319.","journal-title":"N Engl J Med"},{"issue":"2","key":"1903_CR10","doi-asserted-by":"publisher","first-page":"348","DOI":"10.2215\/CJN.09960911","volume":"7","author":"BJ Manns","year":"2012","unstructured":"Manns BJ, Tonelli M. The new FDA labeling for ESA\u2013implications for patients and providers. Clin J Am Soc Nephrol. 2012;7(2):348\u201353.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"1903_CR11","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.2215\/CJN.04601007","volume":"3","author":"RD Kilpatrick","year":"2008","unstructured":"Kilpatrick RD, Critchlow CW, Fishbane S, Besarab A, Stehman-Breen C, Krishnan M, et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol. 2008;3(4):1077\u201383.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"1903_CR12","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/S0272-6386(04)01086-8","volume":"44","author":"Y Zhang","year":"2004","unstructured":"Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis. 2004;44(5):866\u201376.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"1903_CR13","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/ki.2008.295","volume":"74","author":"LA Szczech","year":"2008","unstructured":"Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008;74(6):791\u20138.","journal-title":"Kidney Int"},{"issue":"6","key":"1903_CR14","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1053\/j.ajkd.2016.12.011","volume":"69","author":"N Gupta","year":"2017","unstructured":"Gupta N, Wish JB. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a potential new treatment for anemia in patients with CKD. Am J Kidney Dis. 2017;69(6):815\u201326.","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"1903_CR15","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","volume":"381","author":"N Chen","year":"2019","unstructured":"Chen N, Hao C, Liu BC, Lin H, Wang C, Xing C, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med. 2019;381(11):1011\u201322.","journal-title":"N Engl J Med"},{"issue":"11","key":"1903_CR16","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa1813599","volume":"381","author":"N Chen","year":"2019","unstructured":"Chen N, Hao C, Peng X, Lin H, Yin A, Hao L, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. N Engl J Med. 2019;381(11):1001\u201310.","journal-title":"N Engl J Med"},{"issue":"3","key":"1903_CR17","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.xkme.2020.01.007","volume":"2","author":"A Karaboyas","year":"2020","unstructured":"Karaboyas A, Morgenstern H, Fleischer NL, Vanholder RC, Dhalwani NN, Schaeffner E, et al. Inflammation and erythropoiesis-stimulating agent response in hemodialysis patients: a self-matched longitudinal study of anemia management in the dialysis outcomes and practice patterns study (DOPPS). Kidney Med. 2020;2(3):286\u201396.","journal-title":"Kidney Med"},{"issue":"8","key":"1903_CR18","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1159\/000508100","volume":"144","author":"T Akizawa","year":"2020","unstructured":"Akizawa T, Yamaguchi Y, Otsuka T, Reusch M. A phase 3, multicenter, randomized, two-arm, open-label study of intermittent oral dosing of roxadustat for the treatment of anemia in japanese erythropoiesis-stimulating agent-naive chronic kidney disease patients not on dialysis. Nephron. 2020;144(8):372\u201382.","journal-title":"Nephron"},{"key":"1903_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfab057","author":"E Shutov","year":"2021","unstructured":"Shutov E, Sulowicz W, Esposito C, Tataradze A, Andric B, Reusch M, et al. Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, double-blind, placebo-controlled study (ALPS). Nephrol Dial Transpl. 2021. https:\/\/doi.org\/10.1093\/ndt\/gfab057.","journal-title":"Nephrol Dial Transpl"},{"issue":"3","key":"1903_CR20","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ekir.2020.11.034","volume":"6","author":"DW Coyne","year":"2021","unstructured":"Coyne DW, Roger SD, Shin SK, Kim SG, Cadena AA, Moustafa MA, et al. Roxadustat for CKD-related anemia in non-dialysis patients. Kidney Int Rep. 2021;6(3):624\u201335.","journal-title":"Kidney Int Rep"},{"issue":"3","key":"1903_CR21","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1681\/ASN.2020081150","volume":"32","author":"S Fishbane","year":"2021","unstructured":"Fishbane S, El-Shahawy MA, Pecoits-Filho R, Van BP, Houser MT, Frison L, et al. Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study. J Am Soc Nephrol. 2021;32(3):737\u201355.","journal-title":"J Am Soc Nephrol"},{"key":"1903_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfab191","author":"J Barratt","year":"2021","unstructured":"Barratt J, Andric B, Tataradze A, Schomig M, Reusch M, Valluri U, et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomised, open-label, active-controlled study (DOLOMITES). Nephrol Dial Transpl. 2021. https:\/\/doi.org\/10.1093\/ndt\/gfab191.","journal-title":"Nephrol Dial Transpl"},{"key":"1903_CR23","doi-asserted-by":"crossref","unstructured":"Csiky B SM, Esposito C, Barratt J, Reusch M, Valluri U, Sulowicz W. Roxadustat for the maintenance treatment of anemia in end-stage kidney disease patients on stable dialysis: a European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES). Adv Therapy. 2021.","DOI":"10.1007\/s12325-021-01904-6"},{"key":"1903_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2021.04.007","author":"C Charytan","year":"2021","unstructured":"Charytan C, Manllo-Karim R, Martin ER, Steer D, Bernardo M, Dua SL, et al. A randomized trial of roxadustat in anemia of kidney failure: SIERRAS study. Kidney Int Rep. 2021. https:\/\/doi.org\/10.1016\/j.ekir.2021.04.007.","journal-title":"Kidney Int Rep"},{"key":"1903_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfab051","volume":"25","author":"R Provenzano","year":"2021","unstructured":"Provenzano R, Shutov E, Eremeeva L, Korneyeva S, Poole L, Saha G, et al. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis. Nephrol Dial. 2021;25: gfab051. https:\/\/doi.org\/10.1093\/ndt\/gfab051.","journal-title":"Nephrol Dial"},{"key":"1903_CR26","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1681\/ASN.2020081150","volume":"32","author":"SPC Fishbane","year":"2021","unstructured":"Fishbane SPC, El-Shahawy M, Escudero ET, Rastogi A, Van BP, Frison L, Houser M, Pola M, Little DJ, Guzman N, Pergola PE. Roxadustat versus epoetin alfa for treating anemia in patients with chronic kidney disease on dialysis: the ROCKIES randomized clinical trial. J Am Soc Nephrol. 2021;32:737\u201355.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"1903_CR27","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.ekir.2020.12.018","volume":"6","author":"R Provenzano","year":"2021","unstructured":"Provenzano R, Fishbane S, Szczech L, Leong R, Saikali KG, Zhong M, et al. Pooled analysis of roxadustat for anemia in patients with kidney failure incident to dialysis. Kidney Int Rep. 2021;6(3):613\u201323.","journal-title":"Kidney Int Rep"},{"key":"1903_CR28","doi-asserted-by":"publisher","first-page":"104747","DOI":"10.1016\/j.phrs.2020.104747","volume":"155","author":"J Liu","year":"2020","unstructured":"Liu J, Zhang A, Hayden JC, Bhagavathula AS, Alshehhi F, Rinaldi G, et al. Roxadustat (FG-4592) treatment for anemia in dialysis-dependent (DD) and not dialysis-dependent (NDD) chronic kidney disease patients: a systematic review and meta-analysis. Pharmacol Res. 2020;155:104747.","journal-title":"Pharmacol Res"},{"issue":"4","key":"1903_CR29","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jacc.2014.12.018","volume":"66","author":"KA Hicks","year":"2015","unstructured":"Hicks KA, Tcheng JE, Bozkurt B, Chaitman BR, Cutlip DE, Farb A, et al. 2014 ACC\/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). J Am Coll Cardiol. 2015;66(4):403\u201369.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"1903_CR30","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1111\/dom.13349","volume":"20","author":"E Blind","year":"2018","unstructured":"Blind E, Janssen H, Dunder K, de Graeff PA. The European Medicines Agency\u2019s approval of new medicines for type 2 diabetes. Diabetes Obes Metab. 2018;20(9):2059\u201363.","journal-title":"Diabetes Obes Metab"},{"key":"1903_CR31","unstructured":"Services USDoHaH. Guidance for industry diabetes mellitus: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2021. https:\/\/www.fda.gov\/media\/71297\/download2008. Accessed 15 Jan 2021."},{"issue":"6","key":"1903_CR32","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/ndt\/gft033","volume":"28","author":"F Locatelli","year":"2013","unstructured":"Locatelli F, Barany P, Covic A, De Francisco A, Del Vecchio L, Goldsmith D, et al. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transpl. 2013;28(6):1346\u201359.","journal-title":"Nephrol Dial Transpl"},{"issue":"8","key":"1903_CR33","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/sj.ki.5000312","volume":"69","author":"G Pernod","year":"2006","unstructured":"Pernod G, Bosson JL, Golshayan D, Barro C, Forneris G, Martina G, et al. Phenotypic and genotypic risk factors for cardiovascular events in an incident dialysis cohort. Kidney Int. 2006;69(8):1424\u201330.","journal-title":"Kidney Int"},{"issue":"2","key":"1903_CR34","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/nep.13835","volume":"26","author":"DYH Yap","year":"2021","unstructured":"Yap DYH, McMahon LP, Hao CM, Hu N, Okada H, Suzuki Y, et al. Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF-PH inhibitors. Nephrology (Carlton). 2021;26(2):105\u201318.","journal-title":"Nephrology (Carlton)"},{"issue":"6","key":"1903_CR35","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1053\/j.ajkd.2015.12.020","volume":"67","author":"R Provenzano","year":"2016","unstructured":"Provenzano R, Besarab A, Wright S, Dua S, Zeig S, Nguyen P, et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. Am J Kidney Dis. 2016;67(6):912\u201324.","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"1903_CR36","doi-asserted-by":"publisher","first-page":"e558","DOI":"10.1542\/neo.15-12-e558","volume":"15","author":"V Manja","year":"2014","unstructured":"Manja V, Lakshminrusimha S. Epidemiology and clinical research design, part 1: study types. NeoReviews. 2014;15(12):e558\u201369.","journal-title":"NeoReviews"},{"issue":"5","key":"1903_CR37","doi-asserted-by":"publisher","first-page":"413","DOI":"10.2188\/jea.JE20090066","volume":"20","author":"S Kimura","year":"2010","unstructured":"Kimura S, Sato T, Ikeda S, Noda M, Nakayama T. Development of a database of health insurance claims: standardization of disease classifications and anonymous record linkage. J Epidemiol. 2010;20(5):413\u20139.","journal-title":"J Epidemiol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01903-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01903-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01903-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T05:10:14Z","timestamp":1632805814000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01903-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,14]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1903"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01903-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,14]]},"assertion":[{"value":"24 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}